References
- Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347(8):589–600.
- George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371(7):654–666.
- Loirat C, Fakhouri F, Ariceta G, et al.; HUS International. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31(1):15–39.
- Fakhouri F, Frémeaux-Bacchi V. Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nat Rev Nephrol. 2021;17(8):543–553.
- Palomo M, Blasco M, Molina P, et al. Complement activation and thrombotic microangiopathies. Clin J Am Soc Nephrol. 2019;14(12):1719–1732.
- Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in thrombotic microangiopathies: unraveling Ariadne’s thread into the labyrinth of complement therapeutics. Front Immunol. 2019;10:337.
- Scully M, Cataland S, Coppo P, et al.; International Working Group for Thrombotic Thrombocytopenic Purpura. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15(2):312–322.
- Bayer G, von Tokarski F, Thoreau B, et al. Etiology and outcomes of thrombotic microangiopathies. Clin J Am Soc Nephrol. 2019;14(4):557–566.
- Fakhouri F, Scully M, Provôt F, et al. Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood. 2020;136(19):2103–2117.
- Brocklebank V, Wood KM, Kavanagh D. Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol. 2018;13(2):300–317.
- Manenti L, Gnappi E, Vaglio A, et al. Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature. Nephrol Dial Transplant. 2013;28(9):2246–2259.
- Lusco MA, Fogo AB, Najafian B, et al. AJKD atlas of renal pathology: thrombotic microangiopathy. Am J Kidney Dis. 2016;68(6):e33–e34.
- Fakhouri F, Delmas Y, Provot F, et al. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. Am J Kidney Dis. 2014;63(1):40–48.
- Hu Y-F, Tan Y, Yu X-J, et al. Podocyte involvement in renal thrombotic microangiopathy: a clinicopathological study. Am J Nephrol. 2020;51(9):752–760.
- Yu X-J, Yu F, Song D, et al. Clinical and renal biopsy findings predicting outcome in renal thrombotic microangiopathy: a large cohort study from a single institute in China. ScientificWorldJournal. 2014;2014:680502. 2014:
- Goodship THJ, Cook HT, Fakhouri F, et al.; Conference Participants. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “kidney disease: improving global outcomes” (KDIGO) controversies conference. Kidney Int. 2017;91(3):539–551.
- Levey AS, Stevens LA, Schmid CH, et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612.
- Fakhouri F, Hourmant M, Campistol JM, et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis. 2016;68(1):84–93.
- Caprioli J, Noris M, Brioschi S, et al.; International Registry of Recurrent and Familial HUS/TTP. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108(4):1267–1279.
- Fogo AB, Kashgarian M. Chapter 8 – renal transplantation. In: Fogo A.B, Kashgarian M, editors. Diagnostic atlas of renal pathology. 3rd ed. Amsterdam, Netherlands: Elsevier; 2017. p. 463–489.
- Armstrong GD. The intraclass correlation as a measure of interrater reliability of subjective judgments. Nurs Res. 1981;30(5):314–315, 320a.
- Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–174.
- Koch GG, Landis JR, Freeman JL, et al. A general methodology for the analysis of experiments with repeated measurement of categorical data. Biometrics. 1977;33(1):133–158.
- Barbour SJ, Coppo R, Zhang H, et al.; International IgA Nephropathy Network. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med. 2019;179(7):942–952.
- Kim YJ. A new pathological perspective on thrombotic microangiopathy. Kidney Res Clin Pract. 2022;41(5):524–532.
- Habib R, Gagnadoux MF, Broyer M. [Hemolytic-uremic syndrome in children and arterial hypertension]. Arch Mal Coeur Vaiss. 1981;74 Spec No:37–43.
- Taylor CM, Chua C, Howie AJ, et al.; British Association for Paediatric Nephrology. Clinico-pathological findings in diarrhoea-negative haemolytic uraemic syndrome. Pediatr Nephrol. 2004;19(4):419–425.
- Morel-Maroger L, Kanfer A, Solez K, et al. Prognostic importance of vascular lesions in acute renal failure with microangiopathic hemolytic anemia (hemolytic-uremic syndrome): clinicopathologic study in 20 adults. Kidney Int. 1979;15(5):548–558.
- Mehrazma M, Hooman N, Otukesh H. Prognostic value of renal pathological findings in children with atypical hemolytic uremic syndrome. Iran J Kidney Dis. 2011;5(6):380–385.
- Batal I, Domsic RT, Shafer A, et al. Renal biopsy findings predicting outcome in scleroderma renal crisis. Hum Pathol. 2009;40(3):332–340.
- Thoenes W, John HD. Endotheliotropic (hemolytic) nephroangiopathy and its various manifestation forms (thrombotic microangiopathy, primary malignant nephrosclerosis, hemolytic-uremic syndrome). Klin Wochenschr. 1980;58(4):173–184.